In silico experiments on human bone remodeling to explore the effects of Romosozumab treatment for metabolic diseases

Osteoporosis is a widespread metabolic disease, which causes an increased risk of bone fracture and a poor fracture healing response. Sclerostin, a cytokine produced majorly by osteocytes is said to play an important role in inhibiting bone formation. This project will help elucidate the treatment effects of Romosozumab, a sclerostin inhibitor drug, which has an anabolic as well as an anti-resorptive response on bone health, by modifying an existing agent-based microscale multiphysics (micro-MP) model of bone remodeling. Literature values would be used to evaluate and keep changes in cytokine concentrations and other model parameters physiologic. The model output would be validated using clinical trial data for Romosozumab on several patients with metabolic diseases. This project is in collaboration with Professor Ralph Muller, Lab for Bone Biomechanics, Institute for Biomechanics, ETH, Zurich.

UG Project Type
Name of Faculty